<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-420</article-id><article-id pub-id-type="pmid">19954513</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-420</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>Identification of colorectal cancer patients with tumors carrying the <italic>TP53 </italic>mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Godai</surname><given-names>Ten-i</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>godait@yokohama-cu.ac.jp</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Suda</surname><given-names>Tetsuji</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>suda@gancen.asahi.yokohama.jp</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Sugano</surname><given-names>Nobuhiro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>suganon@kcch.jp</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Tsuchida</surname><given-names>Kazuhito</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tsuchidak@kcch.jp</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Shiozawa</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>shiozawam@kcch.jp</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Sekiguchi</surname><given-names>Hironobu</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>kensa4@kcch.jp</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Sekiyama</surname><given-names>Akiko</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>kensa4@kcch.jp</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Yoshihara</surname><given-names>Mitsuyo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mitsuyo@gancen.asahi.yokohama.jp</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Matsukuma</surname><given-names>Shoichi</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>matsukum@gancen.asahi.yokohama.jp</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Sakuma</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ysakuma@gancen.asahi.yokohama.jp</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Tsuchiya</surname><given-names>Eiju</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>tsuchiya@gancen.asahi.yokohama.jp</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Kameda</surname><given-names>Yoichi</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>kameday@kcch.jp</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Akaike</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>akaikem@kcch.jp</email></contrib><contrib contrib-type="author" corresp="yes" id="A14"><name><surname>Miyagi</surname><given-names>Yohei</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>miyagi@gancen.asahi.yokohama.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital, 1-1-2 Nakao, Asahi-ku, Yokohama, Japan</aff><aff id="I2"><label>2</label>Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 1-1-2 Nakao, Asahi-ku, Yokohama, Japan</aff><aff id="I3"><label>3</label>Molecular Diagnostics, Kanagawa Cancer Center Hospital, 1-1-2 Nakao, Asahi-ku, Yokohama, Japan</aff><aff id="I4"><label>4</label>Department of Pathology, Kanagawa Cancer Center Hospital, 1-1-2 Nakao, Asahi-ku, Yokohama, Japan</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>12</month><year>2009</year></pub-date><volume>9</volume><fpage>420</fpage><lpage>420</lpage><history><date date-type="received"><day>1</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>2</day><month>12</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Godai et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Godai et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/9/420"/><abstract><sec><title>Background</title><p>Although postoperative chemotherapy is widely accepted as the standard modality for Dukes' stage C or earlier stage colorectal cancer (CRC) patients, biomarkers to predict those who may benefit from the therapy have not been identified. Previous <italic>in vitro </italic>and clinical investigations reported that CRC patients with wild-type p53 gene (<italic>TP53)</italic>-tumors benefit from 5-fluorouracil (5-FU) based chemotherapy, while those with mutated <italic>TP53</italic>-tumors do not. However, these studies evaluated the mutation-status of <italic>TP53 </italic>by immunohistochemistry with or without single-strand conformation polymorphism, and the mutation frequency was different from study to study. In addition, the polymorphic status at p53 codon 72, which results in arginine or proline residues (R72P) and is thought to influence the function of the protein significantly, was not examined.</p></sec><sec><title>Methods</title><p>To evaluate the significance of the <italic>TP53 </italic>mutation as a molecular marker to predict the prognosis of CRC patients, especially those who received postoperative chemotherapy, we examined the mutation by direct sequencing from fresh CRC tumors and evaluated the R72P polymorphism of the mutated <italic>TP53 </italic>by a combined mutant allele- and polymorphic allele-specific polymerase chain reaction (PCR).</p></sec><sec><title>Results</title><p>The <italic>TP53 </italic>mutation occurred in 147 (70%) of 211 Japanese CRC tumors. The mutation was observed in 93 (63%) tumors on the R72 allele and in 54 (37%) tumors on the P72 allele. Although the alterations to <italic>TP53 </italic>have no prognostic significance for CRC patients overall, we found that Dukes' stage C CRC patients who did not receive postoperative chemotherapy and carried the mutated <italic>TP53</italic>-R72 showed significantly longer survival times than those with the mutated <italic>TP53</italic>-P72 when evaluated by overall survival (<italic>p = 0.012</italic>).</p></sec><sec><title>Conclusion</title><p>Using a combined mutant allele- and polymorphic allele-specific PCR, we defined the codon 72 polymorphic status of the <italic>TP53 </italic>mutated allele in Japanese CRC patients. We raised a possibility that Dukes' stage C colorectal cancer patients with tumors carrying <italic>TP53 </italic>mutation, especially the P72 allele, benefited from 5-FU based postoperative chemotherapy.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The tumor suppressor, p53, has a central role in stress responses that induce cell cycle arrest, senescence, apoptosis or DNA repair, and preserve genomic stability [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Therefore, dysfunction of the p53 pathway is a hallmark of neoplasms. Approximately half of all human tumors carry an alteration of the gene, <italic>TP53 </italic>[<xref ref-type="bibr" rid="B7">7</xref>]. Alterations of <italic>TP53 </italic>play a significant role in the progression of colorectal cancer (CRC) and may be a clinically useful molecular marker of prognosis or response to treatments such as chemotherapy, radiotherapy or combination of the two. <italic>TP53 </italic>is unique among tumor suppressor genes because its alteration not only results in loss-of-function of the product, but also generates a range of mutants demonstrating a gain-of-function phenotype. Li et al. and Blandino et al. reported that the expression of selected p53 mutants inhibited p53-independent apoptosis induced by the &#x003b3;-irradiation and the anticancer reagents such as doxorubicin, cisplatin and etoposide [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Thereafter, in the last 10 years, the gain-of-function p53 mutants have been under intensive investigation because understanding the precise molecular mechanisms may provide information for personalized management and create promising therapeutic targets to benefit a large number of cancer patients [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p><p>More than 200 single nucleotide polymorphisms (SNPs) have been identified for <italic>TP53</italic>, 19 of which are exonic. Eleven of the exonic SNPs are non-synonymous resulting in an exchange of coding amino acid residues [<xref ref-type="bibr" rid="B10">10</xref>]. One of these SNPs results in either arginine (R) or proline (P) residues at codon 72 (R72P, rs1042522). A decade ago, this SNP gained attention when Storey et al. reported that the wild-type p53 with an arginine residue at codon 72 (hereafter p53-R72) is efficiently degraded by the E6 protein of the oncogenic type human papilloma viruses (HPV) and that p53-R72 homozygotes are at risk for HPV-associated uterine cervical cancer [<xref ref-type="bibr" rid="B12">12</xref>]. In contrast, later reports demonstrated that p53 with a proline residue at codon 72 (hereafter p53-P72) is associated with an increased risk in lung, esophagus, breast, urothelial and colorectal cancers [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. However, other studies did not find any association with colorectal cancer [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. The significance of the polymorphism R72P in association with the risk of cancer development or outcomes of cancer patients remains inconclusive, possibly due to differences in ethnic groups, genetic heterogeneity, sample number, cancer types, and treatment modalities in the each investigated cancer and population.</p><p><italic>TP53 </italic>mutation in combination with the codon 72 polymorphic status has been examined extensively. Selected p53 mutants have been shown to gain the ability to bind to p73, a homologue of p53, and to inactivate the apoptosis pathway mediated by p73. Interestingly, this gain-of-function mutation is influenced by the p53 codon 72 polymorphism, and the mutated p53-R72 bind p73 more efficiently than the mutated p53-P72 [<xref ref-type="bibr" rid="B21">21</xref>]. As a result, the mutated p53-R72 show an enhanced dominant negative influence on the p73L/p73 pathway [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>] and a significantly decreased response to cytotoxic chemotherapeutic reagents [<xref ref-type="bibr" rid="B24">24</xref>]. Although these <italic>in vitro</italic>-findings are partly supported by clinical investigations in several kinds of cancers [<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>], it is not yet addressed in CRC. Thus, in this study, we examined the polymorphism R72P of mutated <italic>TP53 </italic>in relation to the outcome of CRC patients who was received postoperative chemotherapy.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient population and tissue specimens</title><p>The study population consisted of 212 patients (122 men and 90 women; mean age 64.5 years) who had surgical resection of sporadic colorectal cancers during the period from 2002 to 2004 at Kanagawa Cancer Center Hospital. Cancer tissues were obtained from each case, and stored at -80&#x000b0;C until use. Patient outcome was followed either until their death or until July 31, 2008, and all the survival data of this study was restricted to 157 patients who passed at least 4 years after the operation. Demographic and clinicopathological characteristics of the patients included in the study are listed in Table <xref ref-type="table" rid="T1">1</xref>. Pathologic stage was determined using the Dukes' staging system. Histopathologic types were described according to the World Health Organization Classification of Tumors [<xref ref-type="bibr" rid="B28">28</xref>]. Differentiation of adenocarcinomas was evaluated according to the TNM classification [<xref ref-type="bibr" rid="B29">29</xref>]. The number of lymph node metastases of advanced cancer patients was evaluated from pathological reports in at least 12 dissected lymph nodes. Ninety-four patients received postoperative chemotherapy. The 5-FU-based regimens included tegafur and uracil (UFT) following 5-FU: leucovorin (LV)/5-FU (RPMI regimen), 28 cases; LV/5-FU/CPT-11 (FOLFIRI/IFL), 11 cases; LV/UFT-based regimens, 55 cases. Twenty-six patients with Dukes' stage C did not agree to undergoing postoperative chemotherapy. The present study was approved by the institutional ethical review board at Kanagawa Cancer Center, and written informed consent to the study was obtained from all patients. Patients' follow-up data were obtained through a review of hospital and physician's records, by direct contact with the patient or through the social residential registration.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Histological and clinical features of colorectal cancer patients (n = 212)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Gender (Male/Female)</td><td align="center">122/90</td></tr><tr><td align="left">Age (years +/- SD)</td><td align="center">64.5 +/- 10.8</td></tr><tr><td align="left">Primary tumor location</td><td/></tr><tr><td align="left">&#x02003;Colon</td><td align="center">114</td></tr><tr><td align="left">&#x02003;Rectum</td><td align="center">98</td></tr><tr><td align="left">Dukes' stage, (%)</td><td/></tr><tr><td align="left">&#x02003;A</td><td align="center">42 (19.8)</td></tr><tr><td align="left">&#x02003;B</td><td align="center">61 (28.8)</td></tr><tr><td align="left">&#x02003;C</td><td align="center">75 (35.4)</td></tr><tr><td align="left">&#x02003;D</td><td align="center">34 (16.0)</td></tr><tr><td align="left">Histopathological grade, (%)</td><td/></tr><tr><td align="left">&#x02003;G1</td><td align="center">44 (20.8)</td></tr><tr><td align="left">&#x02003;G2</td><td align="center">135 (63.7)</td></tr><tr><td align="left">&#x02003;G3</td><td align="center">33 (15.6)</td></tr><tr><td align="left">Postoperative treatment</td><td/></tr><tr><td align="left">&#x02003;Chemotherapy</td><td align="center">94</td></tr><tr><td align="left">&#x02003;No therapy</td><td align="center">118</td></tr></tbody></table><table-wrap-foot><p>SD, standard deviation.</p></table-wrap-foot></table-wrap></sec><sec><title>Nucleic acid preparation and cDNA synthesis</title><p>Genomic DNA was isolated from tumor tissues using the QIAamp DNA Mini Kit (Qiagen KK, Tokyo, Japan) according to the manufacture's instructions. RNA was extracted with the TRIZOL<sup>&#x000ae; </sup>Reagent (Invitrogen, Carlsbad, CA), following the manufacture's instructions. First-strand cDNA was synthesized with an oligo(dT)<sub>12-18 </sub>primer and the SuperScript<sup>&#x000ae; </sup>First-Strand Synthesis System for RT-PCR (Invitrogen).</p></sec><sec><title><italic>TP53 </italic>mutation analysis</title><p>Mutational analysis of <italic>TP53 </italic>was performed by direct sequencing. Briefly, a 1.64 kb fragment of <italic>TP53 </italic>(corresponding to exons 5-8) was amplified from genomic DNA extracted from each tumor by polymerase chain reaction (PCR). The PCR products were purified and directly sequenced using GenomeLab&#x02122; DTCS Quick Start Kit and the CEQ&#x02122; 2000XL DNA Analysis System (Beckman Coulter, Inc., Fullerton, CA). The obtained nucleotide sequences were compared with the <italic>TP53 </italic>reference sequence (GenBank accession number <ext-link ext-link-type="gen" xlink:href="X54156">X54156</ext-link>). The primers used to amplify exons 5-8 of <italic>TP53 </italic>are available on request.</p></sec><sec><title>Determination of the <italic>TP53 </italic>codon 72 polymorphic status of tumors</title><p>For the determination of polymorphism at codon 72 of <italic>TP53</italic>, an allele-specific PCR assay was used as described previously [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B30">30</xref>] with minor modifications. The precise information for PCR conditions is provided in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p><p>For the <italic>TP53 </italic>mutated tumors with arginine/proline heterogeneous polymorphic status at codon 72, a combined method of the polymorphic allele-specific [<xref ref-type="bibr" rid="B31">31</xref>] and the mutant allele-specific [<xref ref-type="bibr" rid="B32">32</xref>] PCR was performed to determine whether the <italic>TP53 </italic>mutation occurred on the arginine allele or on the proline allele. Briefly, the method was designed to place the polymorphic nucleotides at the 3'-end of the forward primers and the mutated sites at the 3'-end of the reverse primers. The nucleotide sequences of the two polymorphic allele specific primers were 5'-gaggctgctccccg-3' for the arginine allele and 5'-gaggctgctccccc-3' for the proline allele. The nucleotide sequences of the reverse primers, specific to each mutation site, are listed in Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>. The precise information for PCR conditions is also provided in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p></sec><sec><title>Statistical Methods</title><p>The relationship between the codon 72 polymorphic status of the mutated allele of <italic>TP53 </italic>and individual clinicopathological variables were assessed using chi-square tests. Overall survival curves were generated by Kaplan-Meier analysis, and the log rank test was used to compare between survival curves. Differences were considered significant when a P value &#x0003c; 0.05 was obtained. All the statistic analyses were performed by SPSS version 15 for Windows (SPSS Inc. Chicago, IL).</p></sec></sec><sec><title>Results</title><sec><title><italic>TP53 </italic>codon 72 polymorphic status of the tumors</title><p>We analyzed the polymorphic status of the <italic>TP53 </italic>codon 72 by allele-specific PCR analysis. As shown in Table <xref ref-type="table" rid="T2">2</xref>, the allele frequencies were determined as 42% (89 tumors) for the arginine allele, 45% (94 tumors) for the heterozygous arginine/proline status, and 13% (28 tumors) for the proline allele, respectively. There was no significant difference in the overall patient survival among the three codon 72 status groups as assessed by the Kaplan-Meier analysis (Figure <xref ref-type="fig" rid="F1">1a</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Genotype frequencies at codon 72 of <italic>TP53 </italic>in colorectal cancer patients (n = 211)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Arg</th><th align="center">Arg/Pro</th><th align="center">Pro</th><th align="center">P value</th></tr></thead><tbody><tr><td align="left">Cases, n (%)</td><td align="center">89 (42.2)</td><td align="center">94 (44.5)</td><td align="center">28 (13.3)</td><td/></tr><tr><td align="left">Age (years +/- SD)</td><td align="center">64.7 +/- 10.8</td><td align="center">64.8 +/- 11.2</td><td align="center">63.2 +/- 10.2</td><td/></tr><tr><td align="left">Size (cm), n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x0003c;5</td><td align="center">48 (42.5)</td><td align="center">52 (46.0)</td><td align="center">13 (11.5)</td><td/></tr><tr><td align="left">&#x02003;&#x02265; 5</td><td align="center">41 (41.8)</td><td align="center">42 (42.9)</td><td align="center">15 (15.3)</td><td align="center">0.707</td></tr><tr><td align="left">p53 mutations, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;wt</td><td align="center">22 (34.4)</td><td align="center">32 (50.0)</td><td align="center">10 (15.6)</td><td/></tr><tr><td align="left">&#x02003;mt</td><td align="center">67 (45.6)</td><td align="center">62 (42.2)</td><td align="center">18 (12.2)</td><td align="center">0.313</td></tr><tr><td align="left">Mutations by codon 72 status, n</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Mutation on Arg</td><td align="center">67</td><td align="center">26</td><td align="center">-</td><td/></tr><tr><td align="left">&#x02003;Mutation on Pro</td><td align="center">-</td><td align="center">36</td><td align="center">18</td><td/></tr><tr><td align="left">Dukes' stage, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;A</td><td align="center">17 (40.5)</td><td align="center">21 (50.0)</td><td align="center">4 (9.5)</td><td/></tr><tr><td align="left">&#x02003;B</td><td align="center">25 (41.7)</td><td align="center">27 (45.0)</td><td align="center">8 (13.3)</td><td/></tr><tr><td align="left">&#x02003;C</td><td align="center">31 (41.3)</td><td align="center">30 (40.0)</td><td align="center">14 (18.7)</td><td/></tr><tr><td align="left">&#x02003;D</td><td align="center">16 (47.1)</td><td align="center">16 (47.1)</td><td align="center">2 (5.9)</td><td align="center">0.622</td></tr></tbody></table></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Effect of <italic>TP53 </italic>codon 72 genotype on overall survival in colorectal cancer patients</bold>. (a): The association between the <italic>TP53 </italic>codon 72 genotype and overall survival. (b): Overall survival with <italic>TP53 </italic>mutation on the Arg allele and Pro allele (n = 109. P = 0.120). (c): Overall survival in heterozygous patients with <italic>TP53 </italic>mutation (n = 46, P = 0.056). (d): Overall survival in homo- and hemizygous genotype patients with <italic>TP53 </italic>mutation (n = 63, P = 0.688).</p></caption><graphic xlink:href="1471-2407-9-420-1"/></fig></sec><sec><title><italic>TP53 </italic>mutations of the tumors</title><p><italic>TP53 </italic>mutation occurred in 148 (70%) of the tumors. One patient with tumors heterozygous for the codon 72 polymorphism had two different <italic>TP53 </italic>mutations on each allele. Therefore, we removed this case and used 211 patients for the following analyses (Table <xref ref-type="table" rid="T2">2</xref>). Individual mutations in detail and the codon 72 allelism are shown in Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>, <xref ref-type="supplementary-material" rid="S4">4</xref>. Briefly, we found 107 missense (73%), 8 frameshift (5%), 9 splice (6%), 17 nonsense (12%), 2 missense+nonsense (1%) and 4 other mutations. Silent mutation was considered as wild-type in the present study for analyses. Eleven non-synonymous polymorphisms, including the codon 72 (R72P), are now recognized in <italic>TP53</italic>. We evaluated 5 polymorphic sites except for R72P located in exons 5-8, including V217 M, R267W, P278A, R290H and N311S [<xref ref-type="bibr" rid="B10">10</xref>], respectively. In the present study, all the examined sequences corresponding to the above polymorphic sites matched completely to the <italic>TP53 </italic>reference sequence used, and no exonic non-synonymous polymorphism other than R72P was observed.</p></sec><sec><title><italic>TP53 </italic>codon 72 status with or without mutations and patient outcome</title><p>We determined <italic>TP53 </italic>mutated allele for the 62 tumors heterozygous for the codon 72 polymorphic status. Twenty-six <italic>TP53 </italic>mutations occurred on the arginine allele and 36 mutations occurred on the proline allele (Table <xref ref-type="table" rid="T2">2</xref>). In total, <italic>TP53 </italic>mutation occurred on the arginine allele in 93 tumors (44%) and on the proline allele in 54 tumors (26%) among the 211 informative colorectal cancer samples (Table <xref ref-type="table" rid="T3">3</xref>). The lymph node metastasis was significantly increased with the <italic>TP53 </italic>mutation (p &#x0003c; 0.05, chi-square test; Table <xref ref-type="table" rid="T3">3</xref>). However, the background factors of age, sex, number of lymph node metastasis, tumor size, metastasis, venous involvement and lymphatic involvement were not statistically different between the tumors consisting of the mutated <italic>TP53</italic>-R72 and the tumors with the mutated <italic>TP53</italic>-P72 (data not shown). Likewise, there were no significant differences in the overall survival between patients with the mutated <italic>TP53-</italic>R72 and with the mutated <italic>TP53-</italic>P72 (Figure <xref ref-type="fig" rid="F1">1b</xref>). In the present analysis, we were not able to distinguish tumors with mutated <italic>TP53-</italic>R72 together with wild-type <italic>TP53-</italic>R72 from tumors lacking wild-type <italic>TP53</italic>-R72 by LOH. Concerning <italic>TP53</italic>-P72, the findings were the same. Therefore, we selected tumors with mutated <italic>TP53 </italic>under heterozygous codon 72 status, a definitive retention of the other wild-type allele, and analyzed the overall patient survival. There was a tendency that the mutated <italic>TP53</italic>-P72 showed a poorer prognosis than that of the mutated <italic>TP53-</italic>R72, but the difference was not significant (Figure <xref ref-type="fig" rid="F1">1c</xref>). There was no significant difference in the overall patient survival between patients with the mutated <italic>TP53</italic>-R72 and patients with the mutated <italic>TP53</italic>-P72 under homozygous codon 72 status, which includes both LOH tumors and tumors retaining the homologous wild-type allele. There was also no significant difference in the overall patient survival between the tumors with the mutated <italic>TP53</italic>-R72 and the mutated <italic>TP53</italic>-P72 (Figure <xref ref-type="fig" rid="F1">1d</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><italic>TP53 </italic>mutation and allelism (n = 211)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">No mutation</th><th align="center">Mutation on Arg</th><th align="center">Mutation on Pro</th><th align="center">P value</th></tr></thead><tbody><tr><td align="left">Case, n (%)</td><td align="center">64 (30.3)</td><td align="center">93 (44.1)</td><td align="center">54 (25.6)</td><td/></tr><tr><td align="left">Primary tumor location, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Colon</td><td align="center">35 (31.0)</td><td align="center">51 (45.1)</td><td align="center">27 (23.9)</td><td/></tr><tr><td align="left">&#x02003;Rectum</td><td align="center">29 (29.6)</td><td align="center">42 (42.9)</td><td align="center">27 (27.6)</td><td align="center">0.832</td></tr><tr><td align="left">Site, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Proximal</td><td align="center">18 (36.7)</td><td align="center">17 (34.7)</td><td align="center">14 (28.6)</td><td/></tr><tr><td align="left">&#x02003;Distal</td><td align="center">17 (26.6)</td><td align="center">34 (53.1)</td><td align="center">13 (20.3)</td><td align="center">0.149</td></tr><tr><td align="left">Histopathological grade, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;G1+G2</td><td align="center">50 (28.1)</td><td align="center">79 (44.4)</td><td align="center">49 (27.5)</td><td/></tr><tr><td align="left">&#x02003;G3</td><td align="center">14 (42.4)</td><td align="center">14 (42.4)</td><td align="center">5 (15.2)</td><td align="center">0.167</td></tr><tr><td align="left">Lymph node metastasis, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;N0</td><td align="center">43 (40.6)</td><td align="center">39 (36.8)</td><td align="center">24 (22.6)</td><td/></tr><tr><td align="left">&#x02003;N1</td><td align="center">16 (19.0)</td><td align="center">45 (53.6)</td><td align="center">23 (27.4)</td><td/></tr><tr><td align="left">&#x02003;N2</td><td align="center">5 (23.8)</td><td align="center">9 (42.9)</td><td align="center">7 (33.3)</td><td align="center">0.022*</td></tr><tr><td align="left">Dukes' stage, n (%)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;A</td><td align="center">19 (45.2)</td><td align="center">15 (35.7)</td><td align="center">8 (19.0)</td><td/></tr><tr><td align="left">&#x02003;B</td><td align="center">23 (38.3)</td><td align="center">21 (35.0)</td><td align="center">16 (26.7)</td><td/></tr><tr><td align="left">&#x02003;C</td><td align="center">12 (16.0)</td><td align="center">42 (56.0)</td><td align="center">21 (28.0)</td><td/></tr><tr><td align="left">&#x02003;D</td><td align="center">10 (29.4)</td><td align="center">15 (44.1)</td><td align="center">9 (26.5)</td><td align="center">0.024*</td></tr></tbody></table><table-wrap-foot><p>* The statistical difference is shown by the chi-square test.</p></table-wrap-foot></table-wrap></sec><sec><title>Significance of the codon 72 status on the clinicopathological factors</title><p>The CRC specimens were stratified by the location (colon or rectum), the histological subclasses and the Dukes' stage (Table <xref ref-type="table" rid="T2">2</xref>). The frequency of mutation that occurred on the <italic>TP53</italic>-R72 or -P72 was not statistically different in tumor location or histological subclass (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>The <italic>TP53 </italic>mutation rate showed a tendency to increase with the Dukes' stage progression to stage C. The <italic>TP53 </italic>mutation was 55% (23 out of 42) in Dukes' stage A patients and 84% (63 out of 75) in stage C patients, and this difference was statistically significant (p &#x0003c; 0.05, chi-square test; Table <xref ref-type="table" rid="T3">3</xref>). However, frequency of the mutations that occurred on the <italic>TP53</italic>-R72 or -P72 and the Dukes' stage showed no significant relevance (p &#x0003e; 0.05, chi-square test). In addition, the overall survival of the patients was not different between the mutated alleles and the Dukes' stages (data not shown).</p></sec><sec><title>Significance of the codon 72 status of the mutated <italic>TP53 </italic>on the patient outcome after postoperative chemotherapy</title><p>Fifty-four patients with <italic>TP53 </italic>mutation received postoperative chemotherapy, and there was no significant difference in the overall patient survival between the two codon 72 polymorphic status groups of the mutated alleles (n = 32 for R72 and n = 22 for P72) (p = 0.475; data not shown). Then, we focused on the stage C patients. <italic>TP53 </italic>mutation had no relation to the overall patient survival (Figure <xref ref-type="fig" rid="F2">2a</xref>). And there was no significant difference in the overall survival after postoperative chemotherapy among the patients without <italic>TP53 </italic>mutation (Figure <xref ref-type="fig" rid="F2">2c</xref>). However, all patients, or the patients with <italic>TP53 </italic>mutation, who received postoperative chemotherapy, showed a significantly better survival than the patients without chemotherapy (Figure <xref ref-type="fig" rid="F2">2b, d</xref>). Focusing on the codon 72 polymorphic status of the mutated <italic>TP53</italic>, survival after chemotherapy was not different between the <italic>TP53</italic>-R72 and <italic>TP53</italic>-P72 (Figure <xref ref-type="fig" rid="F3">3a</xref>). By contrast, as concerns the 16 patients with mutated <italic>TP53</italic>, who did not receive postoperative chemotherapy, the patients with the mutated <italic>TP53</italic>-R72 (n = 13) showed significantly longer survival than those with the mutated <italic>TP53</italic>-P72 (n = 3) (p = 0.012; Figure <xref ref-type="fig" rid="F3">3b</xref>). Among the patients with the mutated <italic>TP53</italic>-P72, the patients who received postoperative chemotherapy (n = 15) showed significantly better prognosis than those without chemotherapy (n = 3) (p = 0.012; Figure <xref ref-type="fig" rid="F3">3c</xref>). Although the tendency for a better prognosis was demonstrated by similar analysis, a statistically significant difference was not observed in the patients with the mutated <italic>TP53</italic>-R72 (p = 0.112; Figure <xref ref-type="fig" rid="F3">3d</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Effect of chemotherapy and the <italic>TP53 </italic>mutation in colorectal cancer patients of Dukes' stage C</bold>. (a): Overall survival of Dukes' stage C patients with the <italic>TP53 </italic>mutation and without the mutation (n = 62, P = 0.891). (b): Overall survival of patients with surgical treatment alone and with postoperative chemotherapy (n = 62, P = 0.037). Patients at Dukes' stage C with the <italic>TP53 </italic>mutation did not show significant sensitivity to chemotherapy (c) (n = 11, P = 0.727), but patients with the <italic>TP53 </italic>mutation show a significant effect of chemotherapy (d)(n = 51, P = 0.026).</p></caption><graphic xlink:href="1471-2407-9-420-2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Effect of chemotherapy and the <italic>TP53 </italic>mutation on codon 72 polymorphic allele in Dukes' stage C patients</bold>. (a): Overall survival of a Dukes' stage C and chemotherapy patient with the <italic>TP53 </italic>mutation of the Arg allele and Pro allele (n = 35, P = 0.368). (b): Overall survival of patients without chemotherapy and with <italic>TP53 </italic>mutation of the Arg and Pro allele (n = 16, P = 0.012). Dukes' stage C patients with <italic>TP53 </italic>mutation on the Pro allele show a significant effect of chemotherapy (c) (n = 18, P = 0.012), but the patients with mutation on the Arg allele did not reach statistical significance (d)(n = 33, P = 0.112).</p></caption><graphic xlink:href="1471-2407-9-420-3"/></fig></sec><sec><title><italic>TP53 </italic>mutations showing effective p73 inhibition <italic>in vitro </italic>and the patient outcome</title><p>We tested whether patients with 18 <italic>TP53 </italic>mutated allelotypes [<xref ref-type="bibr" rid="B24">24</xref>] demonstrate a poor prognosis or resistance to postoperative chemotherapy. Twenty-seven patients (5 in Dukes' stage A, 6 in stage B, 11 in stage C, and 5 in stage D) had such tumors. However, there were no statistical differences of survival when compared with the others overall, in each Dukes' stage, in patients that received chemotherapy or in patients without chemotherapy (data not shown).</p></sec></sec><sec><title>Discussion</title><p>Although postoperative adjuvant therapy is accepted widely as the standard modality for stage III, Dukes' stage C or earlier stage CRC patients, Tang et al. reported that one-fourth of stage III patients and two-thirds of stage II patients received no such therapy [<xref ref-type="bibr" rid="B33">33</xref>]. Those patients tended to be older and to have less advanced tumors when compared with those who received postoperative adjuvant therapy. Therefore, predicting the patients who benefit from postoperative adjuvant therapy is important to selectively recommend the therapy and to improve the prognosis.</p><p>Although alterations of <italic>TP53 </italic>appear to have little- or no-prognostic significance for CRC patients treated with surgery alone [<xref ref-type="bibr" rid="B34">34</xref>], several clinical studies have demonstrated that CRC patients with wild-type <italic>TP53</italic>-tumors gain a survival benefit from 5-FU based postoperative chemotherapy, but those with <italic>TP53</italic>-mutated tumors do not [<xref ref-type="bibr" rid="B35">35</xref>-<xref ref-type="bibr" rid="B37">37</xref>]. Westra et al. also showed the same results from stage III colon cancer patients [<xref ref-type="bibr" rid="B35">35</xref>]. These studies were conducted in Australia, Europe and the United States. A large cohort, "the <italic>TP53</italic>-CRC-international collaborative study", which is a meta-analysis study analyzing more than 3,500 CRC patients from 17 countries, also demonstrated that Dukes' C tumors with wild-type <italic>TP53 </italic>showed a significantly better survival when treated with postoperative adjuvant chemotherapy [<xref ref-type="bibr" rid="B38">38</xref>]. This extensive meta-analysis, however, involved 2 Japanese studies with 103 CRC patients, corresponding to only 2.9% of all cases evaluated, and the <italic>TP53 </italic>mutation frequency ranged widely from 31% to 84%. In the present study, we included Japanese CRC patients from a single institute, and observed <italic>TP53 </italic>mutation in 70% of colorectal cancers. The Dukes' stage C patients who received postoperative chemotherapy showed a better overall survival than those who did not. This is consistent with previous investigations. However, the patients that benefited from the 5-FU based postoperative chemotherapy were not the patients with tumors containing wild-type <italic>TP53</italic>, but those with tumors containing <italic>TP53 </italic>mutation. Although Bunz et al. demonstrated <italic>in vitro </italic>that the apoptosis-inducing effect of 5-FU was almost abrogated when they deleted <italic>TP53 </italic>in the wild-type <italic>TP53 </italic>carrying human colon cancer cell, HCT116 [<xref ref-type="bibr" rid="B39">39</xref>], this situation is quite different from the actual clinical setting in which p53 function was knocked out not by homozygous deletion, but by missense mutation. Actually, we found that 72% of the <italic>TP53 </italic>alterations were missense mutation, which may result in gain-of-function oncogenic properties. Our results suggest that the oncogenic property of mutated p53 is involved significantly in the malignant phenotype of these tumors, and that the 5-FU based postoperative chemotherapy is effective.</p><p>Longley et al. reported that 5-FU increased Fas protein expression in the wild-type <italic>TP53 </italic>colon cancer HCT116 cells, but not in the <italic>TP53</italic>-null cells or <italic>TP53-</italic>mutated colon cancer H630 cells [<xref ref-type="bibr" rid="B40">40</xref>]. Our results showed that the tumors carrying the mutation on <italic>TP53</italic>-P72 benefited most from the 5-FU based postoperative chemotherapy seems contradictory to the results of those reports. However, it is unclear what <italic>TP53 </italic>mutation occurred in H630 and how the oncogenic property of p53 gain-of-function mutation in combination with R72P status influences the apoptosis system. Therefore, there may be unknown pathways of apoptosis that function preferentially in colorectal cancer cells with the mutated <italic>TP53</italic>-P72 in response to 5-FU based postoperative chemotherapy.</p><p>Predicting which patients will benefit from the postoperative adjuvant therapy is important to improve CRC prognosis, and the prediction may be different when different adjuvant therapies are performed. In the present study, we identified CRC patients with tumors carrying <italic>TP53 </italic>mutation, especially on the codon 72 proline allele, as those patients that benefited most from 5-FU based postoperative chemotherapy. This result seems to be contradictory to several previous clinical reports or <italic>in vitro </italic>studies, but, we evaluated <italic>TP53 </italic>mutation by direct sequencing on fresh tumor samples and the precise discrimination of polymorphic status of the codon 72 were different from previous studies. The ethnic background of the investigated population may also be responsible for the differences.</p></sec><sec><title>Conclusion</title><p>In the present study, we identified the codon 72 polymorphic status of the <italic>TP53 </italic>mutated allele in CRC patients. We found that Dukes' stage C CRC patients with the mutated <italic>TP53</italic>-R72 who did not receive postoperative chemotherapy showed significantly longer survival times than those with the mutated <italic>TP53</italic>-P72. Our results raised a possibility that Dukes' stage C CRC patients with tumors carrying <italic>TP53 </italic>mutation, especially the P72 allele, benefited most from 5-FU based postoperative chemotherapy, but we need to collect more CRC cases to form definite conclusions.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>TG and TS performed the statistical analysis and drafted the manuscript. TG, TS, HS, AS and MY carried out sequencing and PCR analysis. TG, NS, KT, MS and MA collected and analyzed samples from colorectal cancer patients. YK performed pathological analysis and revised the manuscript. SM, YS, ET reviewed all data, and contributed to the preparation of the manuscript. YM directed the overall project, and participated in the editing of the final manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/420/prepub">http://www.biomedcentral.com/1471-2407/9/420/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Determination of the <italic>TP53 </italic>codon 72 polymorphic status of tumors</bold>. The precise information for PCR conditions.</p></caption><media xlink:href="1471-2407-9-420-S1.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Reverse primers used for mutant-allele-specific amplification</bold>. The nucleotide sequences of the reverse primers, specific to each mutation site.</p></caption><media xlink:href="1471-2407-9-420-S2.XLS" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Individual mutations in detail and the codon 72 allelism</bold>. Precise information for the <italic>TP53 </italic>mutation found in each case was provided.</p></caption><media xlink:href="1471-2407-9-420-S3.XLS" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>Location and frequency of p53 missense mutation in the p53 protein</bold>. The positions of the mutated amino acid of p53 and the number of mutations in exons 5-8 are shown by the black bar. One hundred and five tumors corresponded to transitions (58 G:A and 52 C:T) and 22 transversions (4 A:C, 1 A:T, 14 G:T, and 3 G:C) were identified. Four mutations identified in the present study (c.560-19_560-9del11, c.571-586del16, c.625_628delAGAA and c.673-16_673-4del13) have not been described in the 4 major databases for <italic>TP53 </italic>mutation: the IARC <italic>TP53 </italic>mutation database <ext-link ext-link-type="uri" xlink:href="http://www-p53.iarc.fr/">http://www-p53.iarc.fr/</ext-link> [Petitjean A <italic>et al</italic>., <italic>Hum Mutat </italic>2007], the database of germline p53 mutations <ext-link ext-link-type="uri" xlink:href="http://www.lf2.cuni.cz/projects/germline_mut_p53.htm">http://www.lf2.cuni.cz/projects/germline_mut_p53.htm</ext-link>, the <italic>TP53 </italic>knowledgebase <ext-link ext-link-type="uri" xlink:href="http://p53.bii.a-star.edu.sg/index.php">http://p53.bii.a-star.edu.sg/index.php</ext-link>, and the <italic>TP53 </italic>web site <ext-link ext-link-type="uri" xlink:href="http://p53.free.fr/">http://p53.free.fr/</ext-link>.</p></caption><media xlink:href="1471-2407-9-420-S4.EPS" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>This research was supported by grants from Kanagawa Cancer Research Fund. We thank Mr. Yoshiyasu Nakamura and Ms. Yukiko Yamazaki for their technical assistance. We thank Dr. Naoyuki Okamoto for his assistance with the statistical analyses.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Nakamura</surname><given-names>Y</given-names></name><article-title>Isolation of p53-target genes and their functional analysis</article-title><source>Cancer Sci</source><year>2004</year><volume>95</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03163.x</pub-id><pub-id pub-id-type="pmid">14720320</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Slebos</surname><given-names>RJ</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Plunkett</surname><given-names>BS</given-names></name><name><surname>Kessis</surname><given-names>TD</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Hedrick</surname><given-names>L</given-names></name><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Cho</surname><given-names>KR</given-names></name><article-title>p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>5320</fpage><lpage>5324</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.12.5320</pub-id><pub-id pub-id-type="pmid">8202487</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Naumovski</surname><given-names>L</given-names></name><name><surname>Cleary</surname><given-names>ML</given-names></name><article-title>The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M</article-title><source>Mol Cell Biol</source><year>1996</year><volume>16</volume><fpage>3884</fpage><lpage>3892</lpage><pub-id pub-id-type="pmid">8668206</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><article-title>A model for p53-induced apoptosis</article-title><source>Nature</source><year>1997</year><volume>389</volume><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/38525</pub-id><pub-id pub-id-type="pmid">9305847</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Dameron</surname><given-names>KM</given-names></name><name><surname>Volpert</surname><given-names>OV</given-names></name><name><surname>Tainsky</surname><given-names>MA</given-names></name><name><surname>Bouck</surname><given-names>N</given-names></name><article-title>Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1</article-title><source>Science</source><year>1994</year><volume>265</volume><fpage>1582</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1126/science.7521539</pub-id><pub-id pub-id-type="pmid">7521539</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Shiraishi</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Takei</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><article-title>A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage</article-title><source>Nature</source><year>2000</year><volume>404</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/35003506</pub-id><pub-id pub-id-type="pmid">10716435</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Greenblatt</surname><given-names>MS</given-names></name><name><surname>Bennett</surname><given-names>WP</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><article-title>Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>4855</fpage><lpage>4878</lpage><pub-id pub-id-type="pmid">8069852</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Sutphin</surname><given-names>PD</given-names></name><name><surname>Schwartz</surname><given-names>D</given-names></name><name><surname>Matas</surname><given-names>D</given-names></name><name><surname>Almog</surname><given-names>N</given-names></name><name><surname>Wolkowicz</surname><given-names>R</given-names></name><name><surname>Goldfinger</surname><given-names>N</given-names></name><name><surname>Pei</surname><given-names>H</given-names></name><name><surname>Prokocimer</surname><given-names>M</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name><article-title>Mutant p53 protein expression interferes with p53-independent apoptotic pathways</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><fpage>3269</fpage><lpage>3277</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201867</pub-id><pub-id pub-id-type="pmid">9681825</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><article-title>Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>477</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202314</pub-id><pub-id pub-id-type="pmid">9927204</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Whibley</surname><given-names>C</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name><article-title>p53 polymorphisms: cancer implications</article-title><source>Nat Rev Cancer</source><year>2009</year><volume>9</volume><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nrc2584</pub-id><pub-id pub-id-type="pmid">19165225</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Petitjean</surname><given-names>A</given-names></name><name><surname>Marcel</surname><given-names>V</given-names></name><name><surname>P&#x000e9;tr&#x000e9;</surname><given-names>A</given-names></name><name><surname>Mounawar</surname><given-names>M</given-names></name><name><surname>Plymoth</surname><given-names>A</given-names></name><name><surname>de Fromentel</surname><given-names>CC</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name><article-title>Recent advances in p53 research: an interdisciplinary perspective</article-title><source>Cancer Gene Ther</source><year>2009</year><volume>16</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/cgt.2008.69</pub-id><pub-id pub-id-type="pmid">18802452</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Storey</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Kalita</surname><given-names>A</given-names></name><name><surname>Harwood</surname><given-names>C</given-names></name><name><surname>Gardiol</surname><given-names>D</given-names></name><name><surname>Mantovani</surname><given-names>F</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Leigh</surname><given-names>IM</given-names></name><name><surname>Matlashewski</surname><given-names>G</given-names></name><name><surname>Banks</surname><given-names>L</given-names></name><article-title>Role of a p53 polymorphism in the development of human papillomavirus-associated cancer</article-title><source>Nature</source><year>1998</year><volume>393</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/30400</pub-id><pub-id pub-id-type="pmid">9607760</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Irarr&#x000e1;zabal</surname><given-names>CE</given-names></name><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Aracena</surname><given-names>R</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>C</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><article-title>Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53</article-title><source>Toxicol Lett</source><year>2003</year><volume>144</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S0378-4274(02)00336-3</pub-id><pub-id pub-id-type="pmid">12919725</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Shi</surname><given-names>WL</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Luh</surname><given-names>SP</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Hsieh</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>MT</given-names></name><article-title>Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus</article-title><source>Int J Cancer</source><year>2000</year><volume>89</volume><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/1097-0215(20000920)89:5&#x0003c;458::AID-IJC10&#x0003e;3.0.CO;2-R</pub-id><pub-id pub-id-type="pmid">11008209</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Sj&#x000e4;lander</surname><given-names>A</given-names></name><name><surname>Birgander</surname><given-names>R</given-names></name><name><surname>Hallmans</surname><given-names>G</given-names></name><name><surname>Cajander</surname><given-names>S</given-names></name><name><surname>Lenner</surname><given-names>P</given-names></name><name><surname>Athlin</surname><given-names>L</given-names></name><name><surname>Beckman</surname><given-names>G</given-names></name><name><surname>Beckman</surname><given-names>L</given-names></name><article-title>p53 polymorphisms and haplotypes in breast cancer</article-title><source>Carcinogenesis</source><year>1996</year><volume>17</volume><fpage>1313</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1093/carcin/17.6.1313</pub-id><pub-id pub-id-type="pmid">8681448</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Kuroda</surname><given-names>Y</given-names></name><name><surname>Tsukino</surname><given-names>H</given-names></name><name><surname>Nakao</surname><given-names>H</given-names></name><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Katoh</surname><given-names>T</given-names></name><article-title>p53 Codon 72 polymorphism and urothelial cancer risk</article-title><source>Cancer Lett</source><year>2003</year><volume>189</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(02)00518-9</pub-id><pub-id pub-id-type="pmid">12445680</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>P&#x000e9;rez</surname><given-names>LO</given-names></name><name><surname>Abba</surname><given-names>MC</given-names></name><name><surname>Dulout</surname><given-names>FN</given-names></name><name><surname>Golijow</surname><given-names>CD</given-names></name><article-title>Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>1426</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">16552814</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>ZZ</given-names></name><name><surname>Wang</surname><given-names>AZ</given-names></name><name><surname>Jia</surname><given-names>HR</given-names></name><name><surname>Jin</surname><given-names>XX</given-names></name><name><surname>He</surname><given-names>XL</given-names></name><name><surname>Hou</surname><given-names>LF</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><article-title>Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population</article-title><source>Jpn J Clin Oncol</source><year>2007</year><volume>37</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1093/jjco/hym034</pub-id><pub-id pub-id-type="pmid">17599946</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Sj&#x000e4;lander</surname><given-names>A</given-names></name><name><surname>Birgander</surname><given-names>R</given-names></name><name><surname>Athlin</surname><given-names>L</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Ruteg&#x000e5;rd</surname><given-names>J</given-names></name><name><surname>Beckman</surname><given-names>L</given-names></name><name><surname>Beckman</surname><given-names>G</given-names></name><article-title>P53 germ line haplotypes associated with increased risk for colorectal cancer</article-title><source>Carcinogenesis</source><year>1995</year><volume>16</volume><fpage>1461</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1093/carcin/16.7.1461</pub-id><pub-id pub-id-type="pmid">7614678</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Schneider-Stock</surname><given-names>R</given-names></name><name><surname>Boltze</surname><given-names>C</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Szibor</surname><given-names>R</given-names></name><name><surname>Landt</surname><given-names>O</given-names></name><name><surname>Meyer</surname><given-names>F</given-names></name><name><surname>Roessner</surname><given-names>A</given-names></name><article-title>Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer</article-title><source>Neoplasia</source><year>2004</year><volume>6</volume><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1593/neo.04178</pub-id><pub-id pub-id-type="pmid">15548361</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Marin</surname><given-names>MC</given-names></name><name><surname>Jost</surname><given-names>CA</given-names></name><name><surname>Brooks</surname><given-names>LA</given-names></name><name><surname>Irwin</surname><given-names>MS</given-names></name><name><surname>O'Nions</surname><given-names>J</given-names></name><name><surname>Tidy</surname><given-names>JA</given-names></name><name><surname>James</surname><given-names>N</given-names></name><name><surname>McGregor</surname><given-names>JM</given-names></name><name><surname>Harwood</surname><given-names>CA</given-names></name><name><surname>Yulug</surname><given-names>IG</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Allday</surname><given-names>MJ</given-names></name><article-title>A common polymorphism acts as an intragenic modifier of mutant p53 behaviour</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/75586</pub-id><pub-id pub-id-type="pmid">10802655</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Gaiddon</surname><given-names>C</given-names></name><name><surname>Lokshin</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name><article-title>A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>1874</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.5.1874-1887.2001</pub-id><pub-id pub-id-type="pmid">11238924</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name><article-title>Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2220</fpage><lpage>2225</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210311</pub-id><pub-id pub-id-type="pmid">17401431</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Bergamaschi</surname><given-names>D</given-names></name><name><surname>Gasco</surname><given-names>M</given-names></name><name><surname>Hiller</surname><given-names>L</given-names></name><name><surname>Sullivan</surname><given-names>A</given-names></name><name><surname>Syed</surname><given-names>N</given-names></name><name><surname>Trigiante</surname><given-names>G</given-names></name><name><surname>Yulug</surname><given-names>I</given-names></name><name><surname>Merlano</surname><given-names>M</given-names></name><name><surname>Numico</surname><given-names>G</given-names></name><name><surname>Comino</surname><given-names>A</given-names></name><name><surname>Attard</surname><given-names>M</given-names></name><name><surname>Reelfs</surname><given-names>O</given-names></name><article-title>p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis</article-title><source>Cancer Cell</source><year>2003</year><volume>3</volume><fpage>387</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00079-5</pub-id><pub-id pub-id-type="pmid">12726864</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>McGregor</surname><given-names>JM</given-names></name><name><surname>Harwood</surname><given-names>CA</given-names></name><name><surname>Brooks</surname><given-names>L</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Kelly</surname><given-names>DA</given-names></name><name><surname>O'nions</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>AR</given-names></name><name><surname>Surentheran</surname><given-names>T</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Millard</surname><given-names>TP</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Leigh</surname><given-names>IM</given-names></name><article-title>Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer</article-title><source>J Invest Dermatol</source><year>2002</year><volume>119</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2002.01655.x</pub-id><pub-id pub-id-type="pmid">12164929</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Langer&#x000f8;d</surname><given-names>A</given-names></name><name><surname>Bukholm</surname><given-names>IR</given-names></name><name><surname>Breg&#x000e5;rd</surname><given-names>A</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>Andersen</surname><given-names>TI</given-names></name><name><surname>Rognum</surname><given-names>TO</given-names></name><name><surname>Meling</surname><given-names>GI</given-names></name><name><surname>Lothe</surname><given-names>RA</given-names></name><name><surname>B&#x000f8;rresen-Dale</surname><given-names>AL</given-names></name><article-title>The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2002</year><volume>11</volume><fpage>1684</fpage><lpage>1688</lpage><pub-id pub-id-type="pmid">12496062</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>HH</given-names></name><name><surname>Wilkojmen</surname><given-names>M</given-names></name><name><surname>Marsit</surname><given-names>CJ</given-names></name><name><surname>Kelsey</surname><given-names>KT</given-names></name><article-title>TP53 mutation, allelism and survival in non-small cell lung cancer</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>1770</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi125</pub-id><pub-id pub-id-type="pmid">15905205</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="book"><name><surname>Hamilton</surname><given-names>S</given-names></name><name><surname>Aaltonen</surname><given-names>L</given-names></name><collab>Eds</collab><source>WHO classification of Tumors. Pathology and Genetics of Tumors of the Digestive System</source><year>2000</year><publisher-name>Lyon, IARC press</publisher-name></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="book"><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name><collab>Eds</collab><source>UICC, TNM Classification of Malignant Tumors, 6th ed</source><year>2002</year><publisher-name>New York: John Wiley &#x00026; Sons</publisher-name></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Papadakis</surname><given-names>ED</given-names></name><name><surname>Soulitzis</surname><given-names>N</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><article-title>Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumors arising in Arg/Pro germline heterozygotes</article-title><source>Br J Cancer</source><year>2002</year><volume>87</volume><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600595</pub-id><pub-id pub-id-type="pmid">12434294</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Rust</surname><given-names>S</given-names></name><name><surname>Funke</surname><given-names>H</given-names></name><name><surname>Assmann</surname><given-names>G</given-names></name><article-title>Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection</article-title><source>Nucleic Acids Res</source><year>1993</year><volume>21</volume><fpage>3623</fpage><lpage>3629</lpage><pub-id pub-id-type="doi">10.1093/nar/21.16.3623</pub-id><pub-id pub-id-type="pmid">8367277</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Ichii</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><article-title>Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA)</article-title><source>Hum Mutat</source><year>1993</year><volume>2</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1002/humu.1380020209</pub-id><pub-id pub-id-type="pmid">8318987</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Fan</surname><given-names>CW</given-names></name><name><surname>Tsao</surname><given-names>KC</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Wu</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Changchien</surname><given-names>CR</given-names></name><name><surname>Hsieh</surname><given-names>LL</given-names></name><article-title>p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy</article-title><source>Cancer Lett</source><year>2004</year><volume>210</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2004.01.006</pub-id><pub-id pub-id-type="pmid">15172127</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Iacopetta</surname><given-names>B</given-names></name><article-title>TP53 mutation in colorectal cancer</article-title><source>Hum Mutat</source><year>2003</year><volume>21</volume><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1002/humu.10175</pub-id><pub-id pub-id-type="pmid">12619112</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Westra</surname><given-names>JL</given-names></name><name><surname>Schaapveld</surname><given-names>M</given-names></name><name><surname>Hollema</surname><given-names>H</given-names></name><name><surname>de Boer</surname><given-names>JP</given-names></name><name><surname>Kraak</surname><given-names>MM</given-names></name><name><surname>de Jong</surname><given-names>D</given-names></name><name><surname>ter Elst</surname><given-names>A</given-names></name><name><surname>Mulder</surname><given-names>NH</given-names></name><name><surname>Buys</surname><given-names>CH</given-names></name><name><surname>Hofstra</surname><given-names>RM</given-names></name><name><surname>Plukker</surname><given-names>JT</given-names></name><article-title>Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>5635</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.096</pub-id><pub-id pub-id-type="pmid">16110022</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>JT</given-names></name><name><surname>Huang</surname><given-names>KC</given-names></name><name><surname>Cheng</surname><given-names>YM</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Yeh</surname><given-names>KH</given-names></name><name><surname>Wang</surname><given-names>SM</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><article-title>P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection</article-title><source>Int J Cancer</source><year>2002</year><volume>97</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1002/ijc.1637</pub-id><pub-id pub-id-type="pmid">11802206</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Ahnen</surname><given-names>DJ</given-names></name><name><surname>Feigl</surname><given-names>P</given-names></name><name><surname>Quan</surname><given-names>G</given-names></name><name><surname>Fenoglio-Preiser</surname><given-names>C</given-names></name><name><surname>Lovato</surname><given-names>LC</given-names></name><name><surname>Bunn</surname><given-names>PA</given-names><suffix>Jr</suffix></name><name><surname>Stemmerman</surname><given-names>G</given-names></name><name><surname>Wells</surname><given-names>JD</given-names></name><name><surname>Macdonald</surname><given-names>JS</given-names></name><name><surname>Meyskens</surname><given-names>FL</given-names><suffix>Jr</suffix></name><article-title>Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>1149</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">9515799</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Bazan</surname><given-names>V</given-names></name><name><surname>Iacopetta</surname><given-names>B</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Gebbia</surname><given-names>N</given-names></name><collab>TP53-CRC Collaborative Study Group</collab><article-title>The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>7518</fpage><lpage>7528</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.00.471</pub-id><pub-id pub-id-type="pmid">16172461</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Bunz</surname><given-names>F</given-names></name><name><surname>Hwang</surname><given-names>PM</given-names></name><name><surname>Torrance</surname><given-names>C</given-names></name><name><surname>Waldman</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dillehay</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><article-title>Disruption of p53 in human cancer cells alters the responses to therapeutic agents</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1172/JCI6863</pub-id><pub-id pub-id-type="pmid">10430607</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Longley</surname><given-names>DB</given-names></name><name><surname>Allen</surname><given-names>WL</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Wilson</surname><given-names>TR</given-names></name><name><surname>Latif</surname><given-names>T</given-names></name><name><surname>Boyer</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name><name><surname>Johnston</surname><given-names>PG</given-names></name><article-title>The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>3562</fpage><lpage>3571</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0532</pub-id><pub-id pub-id-type="pmid">15161716</pub-id></mixed-citation></ref></ref-list></back></article>